Cargando…

Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: A retrospective study of international pharmacovigilance database

BACKGROUND: Mogamulizumab (Moga) is a C—C chemokine receptor-4 antibody approved in the United States for relapsed /refractory mycosis fungoides and Sézary syndrome. Few cases reported an increased risk of hepatitis B reactivation and cytomegalovirus (CMV) related infection post-Moga. However, liter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shuai, Jayarangaiah, Apoorva, Malone, Mariuxi, Elrafei, Tarek, Steinberg, Lewis, Kumar, Abhishek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700953/ https://www.ncbi.nlm.nih.gov/pubmed/33294815 http://dx.doi.org/10.1016/j.eclinm.2020.100601

Ejemplares similares

Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases
por: Wang, Jingjing, et al.
Publicado: (2022)

Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database
por: Wang, Jingjing, et al.
Publicado: (2022)

COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response
por: Jayarangaiah, Apoorva, et al.
Publicado: (2020)

Alopecia areata after mogamulizumab treatment
por: Raval, Neel S., et al.
Publicado: (2021)

Left gonadal vein thrombosis in a patient with COVID-19-associated coagulopathy
por: Veyseh, Maedeh, et al.
Publicado: (2020)

Alopecia areata-like presentations with mogamulizumab therapy
por: Kincaid, Colin M., et al.
Publicado: (2023)

Marketing approval of mogamulizumab: A triumph for glyco-engineering
por: Beck, Alain, et al.
Publicado: (2012)

Incidental Asymptomatic Splenic Infarct in a COVID-19 Patient
por: Ghalib, Natasha, et al.
Publicado: (2021)

Potential and Pitfalls of Pharmacovigilance Databases in Oncology
por: Schlam, Ilana, et al.
Publicado: (2023)

Sjögren’s syndrome and Neuromyelitis Optica spectrum disorders (NMOSD) – a case report and review of literature
por: Jayarangaiah, Apoorva, et al.
Publicado: (2014)

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
por: Ollila, Thomas A, et al.
Publicado: (2019)

Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma
por: Kwan, Jennifer M., et al.
Publicado: (2021)

Tocilizumab: Cytomegalovirus reactivation and acute hepatitis: case report
Publicado: (2021)

Psychotropic drugs cross-reactivity with amphetamines in a FAERS sample: an international pharmacovigilance study
por: Giacovelli, L., et al.
Publicado: (2022)

Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database
por: Rudolph, Annette, et al.
Publicado: (2021)

Chemotherapy induced right ventricular cardiomyopathy; a systematic review and meta-analysis
por: Theetha Kariyanna, Pramod, et al.
Publicado: (2023)

Mogamulizumab Treatment in a Hemodialysis Patient with Adult T-Cell Leukemia/Lymphoma
por: Yoshihara, Mari, et al.
Publicado: (2014)

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
por: Fujimura, Taku, et al.
Publicado: (2018)

Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
por: Watson, Sutton, et al.
Publicado: (2019)

Safety and effectiveness of mogamulizumab in relapsed or refractory adult T‐cell leukemia‐lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2019)

Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash
por: Trum, Nicholas A., et al.
Publicado: (2021)

Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor
por: Lama, Carine M., et al.
Publicado: (2023)

Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
por: Allouchery, Marion, et al.
Publicado: (2021)

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
por: Musiek, Amy C. M., et al.
Publicado: (2021)

Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review
por: TRAGER, Megan H., et al.
Publicado: (2020)

Use of Mogamulizumab for Cutaneous Adult T-cell Leukemia in a Patient Living With HIV
por: Boisclair, Stephanie, et al.
Publicado: (2022)

Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas
por: Caruso, Laura, et al.
Publicado: (2022)

Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma
por: Virgen, Cesar A, et al.
Publicado: (2023)

The International Society of Pharmacovigilance (ISoP) Pharmacogenomic Special Interest Group: Pharmacogenomics in Pharmacovigilance
por: Yue, Qun-Ying
Publicado: (2021)

Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study
por: Jouandet, Marie, et al.
Publicado: (2022)

A Systematic Review of COVID-19 and Pericarditis
por: Theetha Kariyanna, Pramod, et al.
Publicado: (2022)

Retrospective review of paediatric case reports of Stevens-Johnson syndrome and toxic epidermal necrolysis with lamotrigine from an international pharmacovigilance database
por: Egunsola, Oluwaseun, et al.
Publicado: (2017)

Chlorpheniramine-induced anaphylaxis: Two case reports and a retrospective review of pharmacovigilance database
por: Lee, So-Hee, et al.
Publicado: (2019)

The Emergence of Epstein-Barr Virus-Related Diffuse Large B-Cell Lymphoma With Mogamulizumab
por: Wang, Lan, et al.
Publicado: (2020)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider
por: Ottevanger, Rosanne, et al.
Publicado: (2022)

Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study
por: Hirosawa, Makoto, et al.
Publicado: (2022)

Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome
por: Beylot‐Barry, Marie, et al.
Publicado: (2022)

PB2345: MOGAMULIZUMAB IN MYCOSIS FUNGOIDES AND SÈZARY SYNDROME: AN ITALIAN SINGLE CENTER EXPERIENCE
por: Simula, Maria Pina, et al.
Publicado: (2023)

International Society of Pharmacovigilance: COVID-19 role
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d6dutf86poa2lhpvlohkgu9cfs